Financial Performance Overview
Zydus Lifesciences Limited reported strong consolidated financial performance for FY 2025-26 with revenue growth of 17% to ₹271.5 billion and EBITDA margin of 31.2% (80 bps improvement). Profit After Tax (exceptional) grew 15% to ₹54.6 billion, while standalone PAT showed 11.4% growth to ₹35.6 billion. The company invested ₹22.7 billion in R&D (8.4% of revenue) and achieved ROCE of 21.6%.
Corporate Actions and Capital Structure
The Board approved significant capital allocation measures including a final dividend of ₹1 per equity share (100%) and a ₹1,100 crore share buyback at ₹1,260 per share. Total dividend payout amounted to ₹11.07 billion. The company's gross debt increased to ₹117.7 billion (debt-to-equity ratio 0.43) from ₹31.7 billion in FY25, primarily funding acquisition activities.
Strategic Acquisitions and Business Expansion
Zydus completed three major acquisitions: Amplitude Surgical SA for €256.8 million entering the MedTech orthopedics space, Comfort Click Limited for GBP 239 million strengthening international wellness presence, and Agenus Inc.'s biologics manufacturing facilities for USD 75 million upfront, marking entry into biologics CDMO business. The company also filed New Drug Application with USFDA for Saroglitazar Magnesium and received approval for Zycubo (copper histidinate injection).
CSR Compliance and Governance
The company reported CSR obligation of ₹548 million but spent only ₹101 million, transferring ₹447 million to unspent account due to delays in establishing 'Zydus Lifesciences University' project. The Board maintained strong governance structure with 9 directors (55% independent, 22% women) and 7 committees. Minor penalties of ₹10,000 each were incurred from BSE and NSE for non-compliance of Regulation 29(1).
Thirty-First Annual General Meeting
The 31st AGM is scheduled for August 11, 2026 at 10:00 AM IST through video conference. Key dates include cut-off for dividend on July 24, 2026, e-voting from August 8-10, 2026, and dividend payment around August 14, 2026. The meeting will seek shareholder approval for dividend declaration and other resolutions.
Subsidiary Performance and Consolidation
Consolidated results showed parent company contributed 87.31% of net assets (₹236.7 billion) and 70.63% of profit (₹35.6 billion). Key subsidiaries included Zydus Healthcare Limited (23.18% net assets, 21.63% profit), Zydus Wellness Limited (14.87% net assets), and Zydus Pharmaceuticals (USA) Inc. (6.16% net assets, 14.52% profit). Exceptional items totaled ₹5.2 billion including litigation settlement, New Labour Codes impact, and acquisition expenses.
Compliance and Regulatory Framework
The company complied with SEBI LODR Regulations, Companies Act 2013, and submitted comprehensive Integrated Annual Report aligned with IIRC framework, GRI Standards, SASB, and SEBI BRSR requirements. Financial statements were audited by Deloitte Haskins & Sells LLP with unmodified opinion, emphasizing litigation provisions in subsidiaries as key audit matter.